16271099

Source:http://linkedlifedata.com/resource/pubmed/id/16271099

Download in:

Switch to

Custom View

Named Graph Language Inference

Statements in which the resource exists as a subject.
Predicate	Object
rdf:type	pubmed:Citation
lifeskim:mentions	umls-concept:C0014792, umls-concept:C0030705, umls-concept:C0036043, umls-concept:C0282461, umls-concept:C0332293, umls-concept:C0450254, umls-concept:C0524727, umls-concept:C2348767, umls-concept:C2350458
pubmed:issue	11
pubmed:dateCreated	2005-11-7
pubmed:abstractText	A randomized, double-blind trial is reported of the clinical efficacy of red blood cells (RBCs) treated for pathogen inactivation with S-303, a synthetic labile alkylating agent.
pubmed:language	eng
pubmed:journal	http://linkedlifedata.com/resource/pubmed/journal/0417360
pubmed:citationSubset	IM
pubmed:chemical	http://linkedlifedata.com/resource/pubmed/chemical/Acridines, http://linkedlifedata.com/resource/pubmed/chemical/Alkylating Agents, http://linkedlifedata.com/resource/pubmed/chemical/Antibodies, http://linkedlifedata.com/resource/pubmed/chemical/Nitrogen Mustard Compounds
pubmed:status	MEDLINE
pubmed:month	Nov
pubmed:issn	0041-1132
pubmed:author	pubmed-author:BenjaminRichard JRJ, pubmed-author:ConlanMaureen GMG, pubmed-author:CorashLaurenceL, pubmed-author:LinJin-SyingJS, pubmed-author:McCulloughJeffreyJ, pubmed-author:MintzPaul DPD, pubmed-author:RizzoRobert JRJ, pubmed-author:SnyderEdwardE, pubmed-author:SpotnitzWilliam DWD, pubmed-author:WagesDavidD, pubmed-author:WoodLindseyL
pubmed:issnType	Print
pubmed:volume	45
pubmed:owner	NLM
pubmed:authorsComplete	Y
pubmed:pagination	1739-49
pubmed:dateRevised	2010-11-18
pubmed:meshHeading	pubmed-meshheading:16271099-Acridines, pubmed-meshheading:16271099-Acute Disease, pubmed-meshheading:16271099-Alkylating Agents, pubmed-meshheading:16271099-Anemia, pubmed-meshheading:16271099-Antibodies, pubmed-meshheading:16271099-Antisepsis, pubmed-meshheading:16271099-Cardiac Surgical Procedures, pubmed-meshheading:16271099-Constipation, pubmed-meshheading:16271099-Double-Blind Method, pubmed-meshheading:16271099-Erythrocyte Transfusion, pubmed-meshheading:16271099-Erythrocytes, pubmed-meshheading:16271099-Humans, pubmed-meshheading:16271099-Intraoperative Care, pubmed-meshheading:16271099-Myocardial Infarction, pubmed-meshheading:16271099-Nitrogen Mustard Compounds, pubmed-meshheading:16271099-Postoperative Care, pubmed-meshheading:16271099-Renal Insufficiency, pubmed-meshheading:16271099-Treatment Outcome
pubmed:year	2005
pubmed:articleTitle	Therapeutic efficacy and safety of red blood cells treated with a chemical process (S-303) for pathogen inactivation: a Phase III clinical trial in cardiac surgery patients.
pubmed:affiliation	Joint Program in Transfusion Medicine, Brigham and Women's Hospital, Boston, Massachusetts, USA. benjaminr@usa.redcross.org
pubmed:publicationType	Journal Article, Randomized Controlled Trial, Research Support, Non-U.S. Gov't, Multicenter Study, Clinical Trial, Phase III